Levetiracetam interferes with the L-dopa priming process in MPTP-lesioned drug-naive marmosets

Clinical Neuropharmacology

Volumn 27, Issue 4, 2004, Pages 171-177

  Hill, Michael P ^a   Brotchie, Jonathan M ^b   Crossman, Alan R ^a,c   Bezard, Erwan ^d   Michel, Anne ^e   Grimée, Renee ^e   Klitgaard, Henrik ^e,f  

^a Williams House   (United Kingdom)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CNRS   (France)

^e UCB PHARMA   (Belgium)

^f Preclinical CNS Research   (Belgium)

Author keywords

Depriming; Drug holiday; L dopa induced dyskinesia

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ETIRACETAM; LEVODOPA;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG RECHALLENGE; DYSKINESIA; FEMALE; MALE; MARMOSET; MONOTHERAPY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; VIDEORECORDING;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; CALLITHRIX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSKINESIAS; LEVODOPA; MPTP POISONING; PIRACETAM; RANDOM ALLOCATION; TIME FACTORS;

EID: 4344595583     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000135478.70905.3d     Document Type: Article

References (37)

1. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990;40:340-345.
2. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol. 1997;20:95-115.
3. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med. 1969;280:337-345.
4. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
5. Rascol O. Medical treatment of levodopa-induced dyskinesias. Ann Neurol. 2000;47:S179-S188.
6. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577-588.
7. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord. 1998;13:871-876.
8. Sandyk R, Snider SR. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry. 1986;143:118.
9. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998;50:1323-1326.
10. Weiner WJ, Koller WC, Perlik S, et al. Drug holiday and management of Parkinson disease. Neurology. 1980;30:1257-1261.
11. Goetz CG, Tanner CM, Klawans HL. Drug holiday in the management of Parkinson disease. Clin Neuropharmacol. 1982;5:351-364.
12. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res. 2001;46:259-270.
13. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56:1772-1774.
14. Hill MP, Bezard E, McGuire S, et al. The novel anti-epileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord. 2003; (in press)
15. Bezard E, Hill MP, McGuire SG, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque, submitted 2003.
16. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol. 2000;47:S122-S130.
17. Fox SH, Henry B, Hill MP, et al. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord. 2001;16:642-650.
18. Henry B, Fox SH, Peggs D, et al. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord. 1999;14:744-753.
19. Pearce RK, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesias in the MPTP-treated common marmoset (Callithrix Jacchus). Mov Disord. 1995;10:731-740.
20. Fox SH, Henry B, Hill M, et al. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002;17:1180-1187.
21. Henry B, Fox SH, Crossman AR, et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's Disease. Exp Neurol. 2001;171:139-146.
22. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507-513.
23. Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002;17:887-901.
24. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol. 2000;47:S90-S104.
25. Cenci MA. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids. 2002;23:105-109.
26. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol. 2000;47:S70-S78.
27. Benabid AL, Benazzouz A, Limousin P, et al. Dyskinesias and the subthalamic nucleus. Ann Neurol. 2000;47:S189-S192.
28. Limousin P. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995;345:91-95.
29. Boraud T, Bezard E, Bioulac B, et al. From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol. 2002;66:265-283.
30. Klitgaard H, Matagne A, Grimee R, et al. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure. 2003;12:92-100.
31. Margineanu DG, Klitgaard H. Inhibition of neural hypersynchrony in vitro differentiates levetiracetam from classic antiepileptic drugs. Pharmacol Res. 2000;42:281-285.
32. Margineanu DG, Klitgaard H. Levetiracetam: mechanisms of action. In: Levy RH, ed. Antiepileptic Drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:419-427.
33. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191-206.
34. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001;306:5-8.
35. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
36. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136:659-672.
37. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137-146.